Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 14/20 | 0.49 |
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648939 | 0.79 | PARP1 (0.51) | PARP1ROCK2NAMPT | |
| SCHEMBL3064920 | 0.74 | PARP1 (0.48) | PARP1KDR | |
| SCHEMBL7904331 | 0.74 | ACHE (0.39) | PARP1ACHEKDR | |
| SCHEMBL10263708 | 0.73 | PARP1 (0.67) | PARP1 | |
| SCHEMBL8307734 | 0.73 | PARP1 (0.67) | PARP1 | |
| SCHEMBL3062940 | 0.72 | CHEK1 (0.43) | PARP1KDR | |
| SCHEMBL2779709 | 0.71 | CHEK1 (0.53) | PARP1KDR | |
| SCHEMBL2763303 | 0.71 | PARP1 (0.75) | PARP1 | |
| SCHEMBL2779985 | 0.69 | KDR (0.46) | PARP1KDR | |
| SCHEMBL2780197 | 0.68 | KDR (0.45) | PARP1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119654-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100004220-A1 | Indenoisoquinolinone Analogs and Methods of Use Thereof | INOTEK PHARMACEUTICALS CORPORATION | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | TNNI3, IDH2, GLS | PARP1 188/4885ACHE 1151/4885KDR 577/4885 |
| US-20100004220-A1 | Indenoisoquinolinone Analogs and Methods of Use Thereof | TNNI3, IDH2, GLS | PARP1 188/4885ACHE 1151/4885KDR 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.